Neurology Advisor caught up with Justin Gover, CEO of GW Pharmaceuticals, which is now operating as Greenwich Biosciences in the United States, to discuss the results of the latest trials and what they may mean for the status of cannabidiol as the company continues to push forward towards a New Drug Application with the US Food and Drug Administration for its product Epidiolex®.
Watch the video below and read more about the positive, placebo-controlled trials here:
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Neurology Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Neurology Advisor?
Register now at no charge to access unlimited clinical news with personalized daily picks for you, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.